Teachers Advisors LLC lifted its position in shares of Stemline Therapeutics, Inc. (NASDAQ:STML) by 1.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,397 shares of the biopharmaceutical company’s stock after purchasing an additional 541 shares during the period. Teachers Advisors LLC owned 0.19% of Stemline Therapeutics worth $399,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Stemline Therapeutics by 32.9% during the first quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock worth $7,055,000 after purchasing an additional 204,228 shares during the period. AXA lifted its holdings in Stemline Therapeutics by 44.9% in the second quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock worth $5,789,000 after buying an additional 195,022 shares during the period. Columbus Circle Investors lifted its holdings in Stemline Therapeutics by 58.4% in the second quarter. Columbus Circle Investors now owns 340,219 shares of the biopharmaceutical company’s stock worth $3,130,000 after buying an additional 125,403 shares during the period. Geode Capital Management LLC lifted its holdings in Stemline Therapeutics by 20.3% in the first quarter. Geode Capital Management LLC now owns 159,920 shares of the biopharmaceutical company’s stock worth $1,367,000 after buying an additional 27,029 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Stemline Therapeutics by 36.0% in the first quarter. Bank of New York Mellon Corp now owns 87,091 shares of the biopharmaceutical company’s stock worth $745,000 after buying an additional 23,077 shares during the period. Institutional investors own 49.01% of the company’s stock.

Stemline Therapeutics, Inc. (NASDAQ STML) opened at $14.00 on Wednesday. Stemline Therapeutics, Inc. has a 1-year low of $5.50 and a 1-year high of $14.60.

STML has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Stemline Therapeutics in a report on Friday, November 10th. Cowen and Company restated a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Finally, ValuEngine lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. Stemline Therapeutics presently has a consensus rating of “Buy” and an average target price of $33.40.

ILLEGAL ACTIVITY NOTICE: “Teachers Advisors LLC Has $399,000 Stake in Stemline Therapeutics, Inc. (STML)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/15/teachers-advisors-llc-has-399000-stake-in-stemline-therapeutics-inc-stml.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.